The effect of dose titration and dose tapering on the tolerability of desvenlafaxine in women with vasomotor symptoms associated with menopause

John Christopher G. Gallagher, Robert A. Strzinek, Ru Fong J Cheng, Militza K. Ausmanas, Dorothea Astl, Palma Seljan

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: To determine whether titrating up and tapering down of desvenlafaxine (administered as desvenlafaxine succinate) improves its tolerability in postmenopausal women with vasomotor symptoms (VMS). Methods: In the 1-week titration phase, participants received desvenlafaxine 100 mg/d (no titration), desvenlafaxine 50 mg/d, desvenlafaxine 25 mg/d (4 days) then 50 mg/d (3 days), or desvenlafaxine 25 mg/d. Participants then received open-label desvenlafaxine 100 mg/d for 15 weeks. In the 2-week taper phase, participants received placebo, desvenlafaxine 50 mg/d then placebo (7 days each), desvenlafaxine 50 mg/d then 25 mg/d (7 days each), or desvenlafaxine 50 mg/d every other day. Primary endpoints included nausea incidence during the first 2 weeks of treatment and Discontinuation-Emergent Signs and Symptoms (DESS) Checklist total scores after taper weeks 1 and 2. Results: Nausea incidence was significantly lower for the desvenlafaxine 25 mg/d (19%) and 50 mg/d (22.6%) titration regimens vs. no titration (35.2%; p=0.004 and p=0.035, respectively). At taper week 1, mean DESS scores were significantly lower for desvenlafaxine 50 mg every other day (2.26, p

Original languageEnglish
Pages (from-to)188-198
Number of pages11
JournalJournal of Women's Health
Volume21
Issue number2
DOIs
StatePublished - Feb 1 2012

Fingerprint

Menopause
Nausea
Signs and Symptoms
Desvenlafaxine Succinate
Placebos
Incidence
Checklist

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

The effect of dose titration and dose tapering on the tolerability of desvenlafaxine in women with vasomotor symptoms associated with menopause. / Gallagher, John Christopher G.; Strzinek, Robert A.; Cheng, Ru Fong J; Ausmanas, Militza K.; Astl, Dorothea; Seljan, Palma.

In: Journal of Women's Health, Vol. 21, No. 2, 01.02.2012, p. 188-198.

Research output: Contribution to journalArticle

Gallagher, John Christopher G. ; Strzinek, Robert A. ; Cheng, Ru Fong J ; Ausmanas, Militza K. ; Astl, Dorothea ; Seljan, Palma. / The effect of dose titration and dose tapering on the tolerability of desvenlafaxine in women with vasomotor symptoms associated with menopause. In: Journal of Women's Health. 2012 ; Vol. 21, No. 2. pp. 188-198.
@article{5f4af1de304d463d8ff9a29ae0e3f18e,
title = "The effect of dose titration and dose tapering on the tolerability of desvenlafaxine in women with vasomotor symptoms associated with menopause",
abstract = "Objective: To determine whether titrating up and tapering down of desvenlafaxine (administered as desvenlafaxine succinate) improves its tolerability in postmenopausal women with vasomotor symptoms (VMS). Methods: In the 1-week titration phase, participants received desvenlafaxine 100 mg/d (no titration), desvenlafaxine 50 mg/d, desvenlafaxine 25 mg/d (4 days) then 50 mg/d (3 days), or desvenlafaxine 25 mg/d. Participants then received open-label desvenlafaxine 100 mg/d for 15 weeks. In the 2-week taper phase, participants received placebo, desvenlafaxine 50 mg/d then placebo (7 days each), desvenlafaxine 50 mg/d then 25 mg/d (7 days each), or desvenlafaxine 50 mg/d every other day. Primary endpoints included nausea incidence during the first 2 weeks of treatment and Discontinuation-Emergent Signs and Symptoms (DESS) Checklist total scores after taper weeks 1 and 2. Results: Nausea incidence was significantly lower for the desvenlafaxine 25 mg/d (19{\%}) and 50 mg/d (22.6{\%}) titration regimens vs. no titration (35.2{\%}; p=0.004 and p=0.035, respectively). At taper week 1, mean DESS scores were significantly lower for desvenlafaxine 50 mg every other day (2.26, p",
author = "Gallagher, {John Christopher G.} and Strzinek, {Robert A.} and Cheng, {Ru Fong J} and Ausmanas, {Militza K.} and Dorothea Astl and Palma Seljan",
year = "2012",
month = "2",
day = "1",
doi = "10.1089/jwh.2011.2764",
language = "English",
volume = "21",
pages = "188--198",
journal = "Journal of Women's Health",
issn = "1540-9996",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - The effect of dose titration and dose tapering on the tolerability of desvenlafaxine in women with vasomotor symptoms associated with menopause

AU - Gallagher, John Christopher G.

AU - Strzinek, Robert A.

AU - Cheng, Ru Fong J

AU - Ausmanas, Militza K.

AU - Astl, Dorothea

AU - Seljan, Palma

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Objective: To determine whether titrating up and tapering down of desvenlafaxine (administered as desvenlafaxine succinate) improves its tolerability in postmenopausal women with vasomotor symptoms (VMS). Methods: In the 1-week titration phase, participants received desvenlafaxine 100 mg/d (no titration), desvenlafaxine 50 mg/d, desvenlafaxine 25 mg/d (4 days) then 50 mg/d (3 days), or desvenlafaxine 25 mg/d. Participants then received open-label desvenlafaxine 100 mg/d for 15 weeks. In the 2-week taper phase, participants received placebo, desvenlafaxine 50 mg/d then placebo (7 days each), desvenlafaxine 50 mg/d then 25 mg/d (7 days each), or desvenlafaxine 50 mg/d every other day. Primary endpoints included nausea incidence during the first 2 weeks of treatment and Discontinuation-Emergent Signs and Symptoms (DESS) Checklist total scores after taper weeks 1 and 2. Results: Nausea incidence was significantly lower for the desvenlafaxine 25 mg/d (19%) and 50 mg/d (22.6%) titration regimens vs. no titration (35.2%; p=0.004 and p=0.035, respectively). At taper week 1, mean DESS scores were significantly lower for desvenlafaxine 50 mg every other day (2.26, p

AB - Objective: To determine whether titrating up and tapering down of desvenlafaxine (administered as desvenlafaxine succinate) improves its tolerability in postmenopausal women with vasomotor symptoms (VMS). Methods: In the 1-week titration phase, participants received desvenlafaxine 100 mg/d (no titration), desvenlafaxine 50 mg/d, desvenlafaxine 25 mg/d (4 days) then 50 mg/d (3 days), or desvenlafaxine 25 mg/d. Participants then received open-label desvenlafaxine 100 mg/d for 15 weeks. In the 2-week taper phase, participants received placebo, desvenlafaxine 50 mg/d then placebo (7 days each), desvenlafaxine 50 mg/d then 25 mg/d (7 days each), or desvenlafaxine 50 mg/d every other day. Primary endpoints included nausea incidence during the first 2 weeks of treatment and Discontinuation-Emergent Signs and Symptoms (DESS) Checklist total scores after taper weeks 1 and 2. Results: Nausea incidence was significantly lower for the desvenlafaxine 25 mg/d (19%) and 50 mg/d (22.6%) titration regimens vs. no titration (35.2%; p=0.004 and p=0.035, respectively). At taper week 1, mean DESS scores were significantly lower for desvenlafaxine 50 mg every other day (2.26, p

UR - http://www.scopus.com/inward/record.url?scp=84856647637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856647637&partnerID=8YFLogxK

U2 - 10.1089/jwh.2011.2764

DO - 10.1089/jwh.2011.2764

M3 - Article

VL - 21

SP - 188

EP - 198

JO - Journal of Women's Health

JF - Journal of Women's Health

SN - 1540-9996

IS - 2

ER -